Minimal residual disease in breast cancer: in blood veritas.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24658155.
- Also identified by DOI 10.1158/1078-0432.CCR-14-0370.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A blood-based molecular test might direct recommendations for systemic therapies in patients with early-stage breast cancer undergoing surgery with curative intent. A new study suggests that droplet digital PCR (ddPCR) can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease.
Medical subject headings
- Breast Neoplasms
- DNA, Neoplasm